pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Raltegravir
drug
save

raltegravir potassium

Marketedupdated 3mo ago
by Lupin Ltd
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying raltegravir potassium

  • phase3Renal Transplantation and Raltegravir in HIV-Infected Patientscompletedn=27
  • phase2Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipientscompletedn=14
  • phase2Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRALcompletedn=170
  • phase2Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patientscompletedn=30
  • phase2Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophyterminatedn=48
  • phase4A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimencompletedn=558
  • phase3Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDYcompletedn=61
  • phase4Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patientscompletedn=10
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 28, 2028
~1.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (17)

  • Mar 30, 2032method-of-use (U-1663)US 10772888
  • Apr 21, 2031patentUS 9649311*PED4.7y
  • Oct 21, 2030formulationUS 96493114.2y
  • Jun 2, 2030compositionUS 87717333.8y
  • Jun 2, 2030compositionUS 87717333.8y
  • Jun 2, 2030compositionUS 87717333.8y
  • Sep 11, 2029patentUS 7754731*PED3.1y
  • Sep 11, 2029patentUS 7754731*PED3.1y
  • Sep 11, 2029patentUS 7754731*PED3.1y
  • Sep 11, 2029patentUS 7754731*PED3.1y
  • Sep 11, 2029patentUS 7754731*PED3.1y
  • Mar 11, 2029compositionUS 77547312.6y
  • Mar 11, 2029compositionUS 77547312.6y
  • Mar 11, 2029compositionUS 77547312.6y
  • Mar 11, 2029compositionUS 77547312.6y
  • Mar 11, 2029compositionUS 77547312.6y
  • Jan 28, 2028compositionUS 88526321.4y

News(0)

no news has mentioned this drug yet

brand
Raltegravir
generic
raltegravir potassium
indication
Human Immunodeficiency Virus (HIV) Infections (AIDS)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 27m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?